Regnante Keith 4/A
4/A · Keros Therapeutics, Inc. · Filed Jan 24, 2025
Insider Transaction Report
Form 4/AAmended
Regnante Keith
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2024-01-04$16.00/sh+40,000$640,000→ 40,000 total - Sale
Common Stock
2024-01-04$45.29/sh−40,000$1,811,600→ 0 total
Footnotes (2)
- [F1]This amendment is being filed to correct the Date of Earliest Transaction and the Transaction Date of each transaction listed in Table I.
- [F2]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.